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Abstract. The immune response in early life, as well as                          
the anti-infective capacity of the organism, can be enhanced by 
some probiotic bacteria, especially those of importance in this 
neonatal period. The potential effect of these particular strains 
associated with early life, either isolated from breast milk or 
from baby faeces, on the immune system should be evaluated by 
in vitro and in vivo models of health or infection status                 
before their introduction to babies, for example, in infant 
formulas.              
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Introduction 
  
      In the last few years, interest in the mutualism between hosts and their 
microbiota has increased considerably. The intestinal microbiota affects the  
human physiology by enhancing the epithelial barrier and immune functions, 
among others, both directly and indirectly. These beneficial effects are 
especially relevant in early life, when the immune system is still immature 
[1]. For this reason, it is important to develop strategies to modulate the 
intestinal environment and microbiota composition and functionality, which 
in turn may modulate the mucosal immune system, and therefore the 
systemic immunity.   
 Among the dietary strategies used to enhance the anti-infective response 
of neonates, the use of probiotics is the most studied. It is known that 
probiotics are exogenous micro-organisms that interact with various cellular 
components within the intestinal environment and have a positive impact on 
the host’s health as defined by the International Scientific Association for 
Probiotics and Prebiotics (ISAPP) in 2013 [2], based on the initial one 
suggested by experts in the World Health Organization (WHO) in 2001 and 
in the Food and Agriculture Organization (FAO) [3]. This concept is 
supported by several other organizations such as the Codex, the Institute of 
Food Technologists (IFT), the World Gastroenterology Organization (WGO) 
and the European Food Safety Authority (EFSA). 
 The probiotics themselves or their metabolites are responsible for the 
effects on the immune system. Probiotics can be recognized by the immune 
cells through pattern-recognition receptors specific to microbial components, 
such as peptidoglycan or lipoteichoic acid [4]. This direct recognition 
triggers inflammatory or anti-inflammatory responses, depending on the 
specific strain [5]. Moreover, probiotics might induce intestinal epithelial 
cells to secrete an array of cytokines, therefore influencing immune function 
indirectly [6]. 
 Mechanisms of immunomodulation include the induction of mucus 
production, short chain fatty acid (SCFA) synthesis, macrophage activation, 
stimulation of cytokine and secretory IgA production, and elevated 
production of peripheral immunoglobulins, among others (Fig. 1). During 
infancy, probiotic interventions could be helpful for the maturation of the 
immune system and, therefore, in strengthening the defence mechanisms 
against infections, or even preventing the development of                        
immune-mediated diseases, such as asthma [4].  
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Figure 1. Main mechanisms of probiotics to potentiate the anti-infective capacity and 
modulate the immune system of the organism. 
 
 Not all bacteria induce the same effects in an organism and these 
effects could be different depending on age. In this case, when the target is 
the infant, it would be of interest to assess those types of bacteria obtained 
from a source related to early life, such as probiotics from breast milk or 
baby faces. 
 Rotavirus (RV) is the leading cause of severe diarrhoea among infants 
and young children and, although more standardized studies are needed, 
nowadays there is enough evidence to show that probiotics can help to 
fight against RV and other infectious and intestinal conditions.  
 Despite all the efforts made to evaluate the influence of these probiotic 
bacteria on infants’ immune response, it is difficult to reach a conclusion 
due to the variability of the physiological or disease status studied, the 
numerous varieties of the probiotic strains, as well as the limitations in the 
number of participants. These are the reasons why most currently available 
data describing the effects of these compounds on immune response are 
derived from preclinical and in vitro studies. 
 On the basis of this background, the hypothesis that supports the 
current book chapter is that the immune response as well as the anti-infective 
capacity of the organism in early life can be enhanced by some probiotic 
bacteria derived from a neonatal source. Therefore, considering this 
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hypothesis, the main objective of this work is to show, with three 
particular representative studies, the beneficial effect of probiotic bacteria 
of importance in early life on the immune development and prevention 
against RV infections. The potential effect of these particular strains 
associated with early life, either isolated from breast milk or from baby 
faeces, on the immune system should be evaluated by in vitro and                           
in vivo models before their introduction to babies, for example, in infant 
formulas. 
 
1. In vitro immunomodulatory actions of breast milk probiotics 
 
 Breast milk has been traditionally considered to be sterile; however, 
current scientific studies have shown that it contains cultivable strains of   
at least 19 species of bacteria belonging to at least ten different genera             
(Table 1). Most of the bacteria isolated belong to the genera 
Staphylococcus, Streptococcus, Lactobacillus and Bifidobacterium, and 
some of them have already been used in human nutrition for their probiotic 
activity [7]. Therefore, breast milk constitutes a continuous source of 
commensal and potentially probiotic bacteria, since an infant that 
consumes approximately 800 mL of milk /day would ingest between               
10
5
 and 10
7
 bacteria daily [8]. These findings would suggest that 
breastfeeding helps to shape the immune system’s development early in 
life in order to achieve a competent function of the gut and a balanced 
immune homeostasis. 
 Despite all the advances made in probiotic research there is still a lack 
of a systematic analysis of the immunomodulatory potential of these 
bacterial strains in human cells and relatively little information is available 
regarding their mechanisms of action. For this reason, in the study by 
Pérez Cano et al. [9], the effects of two lactobacillus strains isolated from 
human milk on the modulation of the activation and cytokine profile of 
peripheral blood mononuclear cell (PBMC) subsets in vitro were 
evaluated. Briefly, Lactobacillus salivarius CECT5713 and Lactobacillus 
fermentum CECT5716 at 10
6
 bacteria/mL were co-cultured with PBMC 
(10
6
/mL) from eight healthy donors for 24 h. The activation status (CD69 
expression) of natural killer (NK) cells (CD56
+
), total T cells (CD3
+
), 
cytotoxic T cells (CD8
+
) and helper T cells (CD4
+
) was determined by 
flow cytometry. Regulatory T cells (Treg) were also quantified by 
intracellular Foxp3 evaluation [9]. 
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Table 1. Bacteria isolated from human breast milk. Adapted from Fernández et al. 
[8]. 
 
Genera Species References 
Bifidobacterium adolescentis, bifidum, breve, longum [10–12] 
Enterococcus faecium, faecalis, durans, hirae, mundtii [13–16] 
Kocuria rhizophila  
Lactobacillus acidophilus, fermentum, plantarum ,gasseri, 
crispatus, rhamnosus, salivarius, reuteri, casei, 
gastricus, vaginalis, animalis, brevis, 
helveticus, 
[13–20] 
Lactococcus lactis [14, 15] 
Leuconostoc mesenteroides [14, 15] 
Pediococcus pentosaceus [11, 12] 
Rothia mucilaginosa [14, 15] 
Staphylococcus epidermidis, aureus, capitis, hominis [14, 15, 17] 
Streptococcus mitis, salivarius, oris, parasanguis, lactarius, 
australis, gallolyticus, vestibularis 
[11, 12, 14–
17] 
 
 To our knowledge this is the first time that the effects of these breast 
milk probiotics on specific lymphocyte subsets, including Treg cells, were 
reported. The results obtained in such a study demonstrated that                                 
L. fermentum CECT5716 and L. salivarius CECT5713 – derived from 
breast milk – were potent activators of NK cells by highly increasing their 
proportion through the expression of the activation marker CD69. 
Moreover, both strains were moderate activators of either CD4
+
 or CD8
+          
 
T cells – even though the increase of CD69 expression was not as evident 
as the one above. Finally, there was no impact of the breast milk probiotic 
bacteria on NK-T cell activation status. Thus, both strains have an 
influence on both innate and acquired immunity (Fig. 2). 
 Both milk strains L. fermentum CECT5716 and L. salivarius 
CECT5713, significantly induced a twofold rise in the Treg proportion with 
respect to resting cells (p<0.05), although the percentage of Treg did not 
exceed 1% of the CD4+ T-cell population. 
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Figure 2. Effect of L. fermentum CECT5716 and L. salivarius CECT5713 on the 
expression marker CD69+ of specific lymphocyte subsets from Pérez-Cano et al. [9]. 
Activated A. NK cells, B. NKT cells, C. CD3+ T cells, D. CD8+ T cells and                           
E. CD4+ T cells. Concanavalin A (ConA) was used as positive control. Data are 
expressed as mean  SEM values of 3–8 healthy donors. Differences between 
control, ConA and bacterial species were tested by one-way ANOVA. Significance: 
*P<0.05 vs. control; P<0.05 vs. ConA.  
 
 On the other hand, in order to evaluate the induction ability of a wide 
range of pro- and anti-inflammatory cytokines and chemokines a                   
semi-quantitative method to simultaneously profile the relative levels of 32 
selected cytokines and chemokines was used. The Proteome Profiler TM 
Array with human cytokine array panel A (R&D Systems Europe Ltd., 
Abingdon, UK) used in the study included C5a, CD40L, G-CSF, GM CSF, 
GXCL1,8 and 10–12,CCL1–CCL5, sICAM-1, IFNγ, IL-1a, Il-1b, IL-1ra,            
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-16, IL-17, IL-17E, IL-23,               
IL-27, IL-32a, MIF, Serpin E-1 and TNFα. Furthermore quantification of 
IFNγ, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNFα, TNFβ, 
MIP-1a and MIP-1b was performed using the human Th1/Th2 plex kit from 
Bender Medsystems GmbH (Vienna, Austria) and GM-CSF and                     
TGF-β1/- β2 by ELISA [21].  
 The results showed that human PBMC, either in resting conditions, 
stimulated with LPS or co-cultured with live probiotic bacteria for 24 h 
displayed different patterns of cytokine secretion (Fig. 3). Unstimulated cells 
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did not evidence the expression of most of the molecules studied; however, 
LPS-stimulated cells secreted most of the cytokines and chemokines 
included in the panel, specifically CCL2, CCL5, MIP-1 , MIP-1 , TNF ,    
Il-1 , IL-6, IL-18, GRO  and sICAM-. L. fermentum CECT5716 and             
L. salivarius CECT5713 promoted the secretion of CCL2, CCL5, GRO  and 
sICAM-1; the amounts obtained were similar to those induced by LPS               
(Fig. 3).  
 In addition, the probiotic bacteria were better inducers of TNF ,                 
MIP-1 , Il-1  and IL-18 than LPS and also activated IL-1  and C5a 
production in the PBMC, which were not induced by LPS. Overall, two 
strain-specific effects were found: on the one hand, the L. fermentum 
CECT5716 seem to induce IFN , and on the other, L salivarius CECT5713 
seem to induce GM-CSF, both in a strong way [21].   
 Further quantification of most of the cytokines and chemokines assayed 
above were later confirmed by the human Th1/Th2 plex kit from Bender 
Medsystems GmbH (Vienna, Austria) and by ELISA [21] (Fig. 4). 
 
 
 
Figure 3. Semi-quantitative determination of relative levels of 32 selected cytokines 
and chemokines in the presence of L. fermentum CECT5716 and L. salivarius 
CECT5713. Results derived from Pérez-Cano et al. [9]. 
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Figure 4. IFN-γ and GM-CSF concentration in PBMC co-cultured with L. fermentum 
CECT5716 and L. salivarius CECT5713 media from Pérez-Cano et al. [9]. LPS was 
used as positive control. Data are expressed as mean  SEM values of 3–8 healthy 
donors. Differences between control, LPS and bacterial species were tested by            
one-way ANOVA. Significance: *P<0.05 vs. control; P<0.05 vs. LPS; δ vs.                          
L. fermentum CETC15716. 
 
 In conclusion, this study demonstrates that L. salivarius CECT5713 
and L. fermentum CECT5716 enhanced the activation of NK and T-cell 
subsets and the expansion of Treg cells, suggesting their ability to 
strengthen both innate and adaptive immune responses. Moreover, both 
strains are able to induce a broad array of cytokines in a strain-specific 
manner. It should be stated that L. fermentum and L. salivarius from                                                                                                              
non-breast milk sources also induce the production of a broad array of 
cytokines [21], and their immunomodulatory importance in early life 
should also be further studied. 
 
 2. In vivo effect of probiotics in health: Immune development 
 
 The next step after investigating the immunomodulatory potential of 
early life probiotics in vitro consisted of investigating the in vivo effect of 
the supplementation with these types of bacteria on the maturation of the 
intestinal and systemic immune system during the first stages of 
development. Very few studies have addressed this issue; in one example, 
Rigo-Adrover et al., [22] investigated the impact of Bifidobacterium breve 
M-16V supplementation on some aspects of the immune system 
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development using a neonatal rat as a model. The neonatal rat has been 
considered as a suitable model for immunonutrition studies, because it 
allows the characterization of immune changes during suckling in several 
lymphoid compartments [1]. 
 In the case of B. breve M-16V, although not a breast milk-derived 
probiotic bacteria, it is naturally present in infants’ microbiota and has 
already shown immunomodulatory properties [23–27]. In Rigo Adrover et al.’s 
study, neonatal Lewis rats were supplemented with the probiotic strain or 
with vehicle during a 13-day period and on day 18 of life, splenocytes, 
mesenteric lymph node (MLN) cells and intraepithelial lymphocytes (IEL) 
were isolated as in previous studies adapted to neonatal rats [28, 29]. They 
were later purified, counted, and stained using immunofluorescence 
techniques. Main cell subsets were evaluated as well as intestinal aspects 
such as faecal consistency and immunoglobulin-A (IgA) levels. 
 Briefly, the study evidenced that B. breve M-16V administration 
during the rat suckling period influences the intestinal and systemic 
lymphocyte composition, modulates the percentage of cells expressing 
molecules involved in the interaction with intestinal bacteria such as 
TLR4, and also potentiates the intestinal IgA production. Regarding the 
changes in lymphocyte composition, very few changes were observed. 
Although this nutritional intervention did not seem to potentiate                       
the systemic immune maturation, it increased the proportion of CD8+ NK 
cells in MLN and reduced that of CD4+ IEL and CD8 + TCR + IEL 
[22]. 
 TLR4 presence in splenocytes was not affected by the nutritional 
intervention with the probiotic bacteria. On the contrary, it was increased 
in the MLN cells but not in IEL (Fig. 5A and B). However, the                    
CD4+ T cell subset in the IEL increased the TLR4+ proportion due to the 
B. breve M-16V supplementation, suggesting that this increased            
bacteria–host interaction may have a role in the preparation of the 
intestinal immune system for a stronger response against infections. These 
results are in agreement with other studies conducted in adult animals [30–34]. 
The αEβ7 integrin on the lymphocyte surface allows IEL retention in the 
intestine [35, 36]. For this reason, it was determined in the three 
compartments and although no changes were found in SPL, the percentage 
of MLN cells and IEL expressing αEβ7 integrin was higher in animals fed 
with the probiotic (p<0.05) (Fig. 5C and D). This result was evidenced in 
CD4+CD8, CD4–CD8+ and CD4–CD8 cells in both compartments. 
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 Finally, the administration of the B. breve M-16V strain for 13 days 
during the suckling period enhanced the intestinal IgA production (Fig. 6), 
which is a typical feature of immuno-enhancing probiotic bacteria                    
[22]. 
 
 
 
Figure 5. Surface TLR4 and αEβ7 integrin expression in MLN and IEL lymphocyte 
in reference and B. breve M-16V supplemented rats from Rigo-Adrover et al. [22]. 
Data are expressed as mean  SEM (n = 8 animals/group). Significance: *P<0.05 vs. 
ref. [22]. 
 
 
 
Figure 6. IgA concentration in intestinal washes of 19-day-old rats. Results are 
expressed as ng of IgA/mg of tissue (mean ± SEM, n=8 animals/group) from Rigo-
Adrover et al. [22]. Statistical differences: *p<0.05 vs. ref. [22]. 
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3. In vivo effect of probiotics under infection: Rotavirus 
gastroenteritis 
 
 Rotavirus is the leading cause of severe diarrhoea among infants and 
young children and, although more standardized studies are needed, there is 
evidence that probiotics can help to fight against RV and other infectious 
and intestinal pathologies. In this context, due to its immunomodulatory 
potential, B. breve M-16V strain was also tested as a protective agent in such 
infective processes [22].  
 Briefly, the neonatal rats received the intervention with the B. breve                                  
M 16V from the 3rd to the 21st day of life (almost the entire suckling period) 
by oral gavage. On day 7, RV was orally administered as in previous studies 
[37]. Clinical variables were evaluated by means of scoring stools from 1 to 4 
(diarrhoea index [DI]) based on colour, texture and amount. These scores 
allow the obtained results to be expressed as incidence and severity,                   
as well as the maximum value of the above variables as indicators. 
   
 
  
Figure 7. Effect of the supplementation with Bifidobacterium breve M-16V in             
RV-induced diarrhoea animals from Rigo-Adrover et al. [22]. Diarrhoea production 
was studied by different parameters: A. proportion of animals with diarrhoea (MDA); 
B. diarrhoeic animals (DA); C. duration of the process, D. maximum diarrhoea index 
(MDI);.E. severity; and F. weight of the faecal specimens. Data are expressed as 
mean  SEM (n = 8 animals/group). Significance: *P<0.05 vs. RV. 
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 RV inoculated to 7-day-old animals induced diarrhoea in most of the 
animals for about 3–4 days (Fig. 7). The supplementation with the probiotic 
was able to significantly reduce the maximum proportion of animals with 
diarrhoea (MDA, Fig. 7A) but also the overall course of the diarrhoeic 
animals (DA, Fig. 7B). The B. breve M-16V also reduced the duration of the 
process (Fig. 7C) as well as its severity, as is observed in the lower values of 
the maximum diarrhoea index (MDI, Fig. 7D) and the overall severity 
throughout the process (Fig. 7E). The intervention also reduced the weight of 
the faecal specimens, which were increased due to the RV infection                   
(Fig. 7F). The study also shows how the probiotic modulates the humoral 
immune response against the virus as well as the pattern of faecal                 
short-chain fatty acids (SCFA) and the results derived after its use in a 
synbiotic combination [22]. 
 
4. Probiotics in infant formulas 
 
 There are several international organizations that are responsible for 
making recommendations and standards that must be accomplished when 
preparing formula types 1 and 2, such as the American Academy Committee 
on Pediatrics Nutrition (AAPCON) and the Committee on Nutrition of the 
European Society of Paediatric Gastroenterology, Hepatology and Nutrition 
(ESPGHAN). A summary of the guidance adapted in Spain can be found in 
Table 2. It summarizes the main components, including, for example, the 
proportion of oligosaccharides. 
 Infant formulas type 1 (0––6 months, 650 kcal/day) and infant formulas 
type 2 (6–12 months, 850 kcal/day) are quite different in composition with 
respect to infant formulas type 3 (12–36 months), which do not follow any 
specific guidance for its formulation. 
 The probiotics can be optionally added to these formulations in order to 
better mimic breast milk composition; however, no compilation of data 
showing a list of probiotics present in these types of products is available. 
Due to this fact, a pilot evaluation was performed with a total of 40 samples 
from Spanish stores (10 samples for each type of infant formula 1, 2 and 3 
sold in pharmacies and 10 in supermarkets). The study was performed in 
September–December 2015 (Table 3). Overall, independently of the source 
providing the formula (pharmacy or supermarket) it can be observed that 
only a low proportion of them include probiotics (25%, 10/40); a proportion 
that increases if the synbiotic formulation is considered (30%, 12/40). It must 
be highlighted that depending on the origin of the product                 
(pharmacy or supermarket) we can observe a high difference: 33.3 % (10/30) of 
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Table 2. Infant’s formula composition. From BOE number. 64. Real Decreto 
165/2014 which modifies BOE number. 131. Real Decreto 867/2008, 23 May                 
[38, 39]. 
 
Nutrients Infant formula type 1  
(per 100 kcal)  
Infant formula type 2  
(per 100 kcal) 
Energy (Kcal) 60–70/100 mL 60–70/100 mL 
Carbohydrates (g) 9–14 9–14 
Lactose (g) >4.5 >4.5 
Proteins (g) 1.8–3 1.8–3.5 
Whey protein/casein  60/40 20/80 
Fat (g) 4.4–6.0 4.0–6.0 
Linoleic acid (mg) 300–1200 300–1200 
Natrium (mg) 20–60 20–60 
Potassium (mg) 60–160 60–160 
Calcium (mg) 50–140 50–140 
Phosphorus (mg) 25–90 25–90 
Iron (mg) 0.3–1.3 0.6–2 
Oligosaccharides (g) <0.8 <0.8 
Probiotic bacteria not mentioned not mentioned 
 
formulas provided in pharmacies have probiotics (40%, 12/30 if 
synbiotics are included) whereas none of those found in the supermarkets 
(0%, 0/10) have probiotics in their composition. Regarding the influence 
of the type of formula, types 1, 2 and 3 contain probiotics in similar 
proportions, which comprises between 30 and 40%.  
 In all cases, the proportion of formulas with probiotics are lower than 
those with oligosaccharides (prebiotics), which are always higher than 
40%, with the exception of the type 3 formulas sold in pharmacies which 
have only a 20% presence of prebiotics. This pilot study just highlights 
the low incorporation of probiotics into these types of products.  
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Table 3. Study of presence of probiotics and prebiotics in infant’s formula on the 
Spanish market (2016). Total samples analysed: 40. 
 
 Pharmacy Supermarket 
Content Total 
N=30 (%) 
Type 1 
N=10 
(%) 
Type 2 
N=10 
(%) 
Type 3 
N=10 
(%) 
Total 
N=10 
(%) 
None N=6  
(20%) 
N=2 
(20%) 
N=0 
(0%) 
N=4 
(40%) 
N=6 
(60%) 
Oligosaccharides N=12 
(40%) 
N=5 
(50%) 
N=5 
(50%) 
N=2 
(20%) 
N=4 
(40%) 
Probiotics N=10 
(33.3%) 
N=3 
(30%) 
N=4 
(40%) 
N=3 
(30%) 
N=0 
(0%) 
Synbiotics  N=2  
(6.7%) 
N=0 
(0%) 
N=1 
(10%) 
N=1 
(10%) 
N=0 
(0%) 
  
5. Conclusions 
 
 Overall, early life probiotics have not only demonstrated their 
immunomodulatory potential in vitro and their beneficial effects on immune 
development but also in the context of infection, as is the case of the 
roatavirus-induced gastroenteritis in the neonatal rat model. Further studies 
are needed in order to provide a better understanding of their mechanisms of 
action and whether they can be considered for inclusion in infant formulas or 
supplements, to be used as strategies for promoting the maturation of the 
neonatal immune system or even for protecting against human                
rotavirus-induced diarrhoea in children. Regardless of their presence in 
breast milk and the positive effects of this type of probiotic bacteria, they are 
poorly included in infant formulas. 
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